Skip to main content

Table 1 Baseline characteristics of patients

From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

 ABC/3TC/RPV (n = 66) (%)ABC/3TC/EFV or boosted PIs (n = 104) (%)p-value
Age, years, median (IQR)35 (28–46)30 (30–49)0.04
Male63 (95.4)95 (91.3)0.37
Race  0.40
 Chinese45 (68.2)73 (70.2) 
 Malay16 (24.2)21 (20.2)
 Indian5 (7.5)5 (4.8)
 Others0 (0)5 (4.8)
HIV transmission route  0.20
 Homosexual42 (63.6)54 (52) 
 Heterosexual12 (18.2)30 (28.9)
 Bisexual8 (12.1)18 (17.3)
 IVDU + sexual contact2 (3.0)1 (1.1)
 Others2 (3.0)1 (1)
Baseline viral load (copies/ml)  0.42
 < 10,00021 (31.8)24 (23.1) 
 10,000–50,00034 (51.5)58 (55.8)
 > 50,00011 (16.7)22 (21.2)
Baseline CD4 count  0.37
 200–35021 (31.8)44 (42.3) 
 > 350–50021 (31.8)30 (28.8)
 > 50024 (36.4)30 (28.8)
AIDS defining illness0 (0)0 (0)NA
HCV co-infection2 (3.0)3 (2.9)0.95
Genotype test at diagnosis29 (44.0)55 (52.9)0.26
Time from diagnosis to treatment, days, median (IQR)67 (45–215)84 (48–351)0.27
HLA B*5701  <0.01
 Positive0 (0)1 (1.0) 
 Negative61 (92.4)65 (62.5)
 Not done5 (7.6)38 (36.5)
Comorbidities   
 Diabetes mellitus5 (7.5)6 (5.8)0.64
 Hypertension7 (10.6)9 (8.6)0.67
 Hyperlipidemia5 (7.6)9 (8.7)0.80
 IHD/CAD1 (1.5)2 (1.9)0.84
 Congestive cardiac failure0 (0)0 (0)NA
 Chronic liver disease0 (0)0 (0)NA
 Chronic kidney disease0 (0)3 (2.9)0.16
 Cancer0 (0)1 (1)0.42
 CVA0 (0)0 (0)NA
 Osteoporosis0 (0)0 (0)NA
  1. ABC abacavir, 3TC lamivudine, RPV rilpivirine, IQR interquartile range, IVDU intravenous drug use, AIDS acquired immunodeficiency syndrome, HCV hepatitis C Virus, IHD ischaemic heart disease, CAD coronary artery disease, CVA cerebrovascular accident